Ann: Activities Update Qtr Ending December 2020 and Appendix 4C, page-9

They were averaging $200k QoQ last year and looks like $400k is new QoQ this year so they should be able to cover OPEX and be CF+ in near term quite easily.

Ex RESMED CFO (Carl) just joined - judging by his LINKEDIN I would say he did a pretty good job at RESMED as he was there for several years and promoted internally.

I have noticed a few competitors coming into this 3D printing space, I am working on a market analysis report if anyone would like a copy, let me know.

OSX is very well positioned to become a market leader thanks to our long history of clinical data. New entrants face a long pathway into this space (clinical studies, regulatory approvals etc). Personalised implants is a booming segment in the orthopaedic industry. Patience and accumulation will pay off here in my opinion.